H2 Equity Partners agrees to acquire Optegra

Dr Peter Byloos, CEO, Optegra

H2 Equity Partners (H2) has agreed to acquire pan European ophthalmology group Optegra from Eight Roads Ventures.

Financial details of the transaction have not been disclosed but subject to regulatory approval, the deal is expected to complete early in 2021.

Eight Roads – a proprietary investment arm of investment house Fidelity – has backed Optegra since it was established in 2007 with a single site in Guildford, Surrey.

The company now operates 23 facilities across the UK, Czech Republic and Poland. Seven of these are in the UK, including its £12m flagship hospital in central London.

As well as the provision of critical eye care services, including cataract surgery and AMD, to the NHS, Optegra offers a wide range of vision correction services and holds ‘top three’ market positions in each of the geographies where it operates.

H2 said it would work closely with the existing management team led by CEO Dr Peter Byloos, who joined the firm in 2017, to deliver an ‘ambitious growth strategy’.

The deal represents the ninth investment for H2 Equity Partners Fund V, which was launched in February 2017 to invest in the UK, Ireland and the Benelux.